Abstract: In a fuel composition containing a static dissipator additive, a Fischer-Tropsch derived fuel component is blended for the purpose of increasing the electrical conductivity of the composition and/or for reducing the concentration of the static dissipator additive in the composition. The fuel composition is preferably an automotive diesel fuel composition.

Abstract: A method for increasing the cetane number of a fuel composition containing a Fischer-Tropsch derived fuel component, in order to reach a target cetane number X, is provided by adding to the composition a concentration c of an ignition improver, wherein c is lower than the concentration which theory would predict needed to be added in order to achieve the target. The ignition improver is preferably 2-ethylhexyl nitrate and the fuel composition suitably a diesel or kerosene fuel. A fuel composition for use in a compression ignition engine, which has a cetane number of 85 or greater, and contains a Fischer-Tropsch derived fuel component and an ignition improver is also disclosed.

Abstract: A composition having a density at 15° C. of between 820 and 845 kg/m3 and a cetane number of equal or greater than 40, which composition has been obtained by blending the following components: (a) a cracked gas oil, (b) a mineral derived gas oil other than (a), and (c) a Fischer-Tropsch derived kerosene fraction; and the use of this composition as an automotive gas oil fuel composition.

Abstract: The present invention provides O-nitro compound, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

Abstract: This thermoplastic elastomer is present in a substantially solid state suitable for use as a binder for a propellant, explosive, and/or gas generant of a supplemental restraint system. The thermoplastic elastomer is formed from a composition including A blocks which are crystalline at temperatures below about 75° C. and B blocks which are amorphous at temperatures above about ?20° C. The A blocks are derived from oxetane derivatives and the B blocks are derived from oxiranes and derivatives thereof. The A blocks and B-blocks are end-capped with a diisocyanate having a first isocyanate moiety that is substantially more reactive with the terminal groups of the blocks than the second isocyanate moiety, whereby the more reactive first isocyanate moiety is capable of reacting with the terminal groups of the blocks, leaving the less reactive second isocyanate moiety free and unreacted.

Abstract: The use of magnesium oxide of specified, low, reactivity in a process for the production of overbased magnesium sulphonates, together with the introduction of water and an alcohol, into the reaction mixture during carbonation, makes it possible to prepare high base number products which have very low post carbonation sediments and which can be purified by rapid filtration.